A series of pilot studies to quantifypathological aggregates in CSF from patients with synucleinopathies usingRT-QuIC and highly purified recombinant α-synuclein have demonstrated thesignificant potential of this approach in advancing laboratory-basedneurodiagnostics. The gene discussed is SNCA; the disease is synucleinopathy.